Novo Nordisk completed the €10.66 billion acquisition of Catalent, including three production plants to scale up Wegovy production. Despite rivals' opposition, the deal secures Novo’s market...
Wegovy stands as Novo Nordisk's big bet. This medicine was what placed the Danish multinational company as the most valuable company in Europe last September, surpassing...